PARP inhibitor clinical trials for prostate cancer were recently reviewed and analyzed extensively, so here, we will summarize several major trials for four PARP inhibitors that have been tested in mCRPC: Olaparib, Rucaparib, Niraparib, and Talazaporib [97,98,99]. This evidence concerns the gene PARP1 and Familial prostate cancer.